Gaudium IVF & Women Health Ltd IPO
IPO Timeline
Category-wise Subscription
| Category | Sub (x) | Offered | Bid For | Amt (Cr)* |
|---|---|---|---|---|
| QIB | — | 10,443,100 (50%) | — | ₹8,250 Cr |
| NII (HNI) | — | 3,132,930 (15%) | — | ₹2,475 Cr |
| Retail | — | 7,310,170 (35%) | — | ₹5,775 Cr |
| Σ Total | — | 20,886,200 (100%) | — | ₹165,001 Cr |
Only available investor categories are shown. Amount is auto-calculated when shares offered and issue price are available.
Issue Details
Minimum Investment (Lot-wise)
| Category | Lots | Shares | Amount (₹) |
|---|---|---|---|
| Retail (Min) | 1 | 189 | ₹14,931 |
| Retail (Max) | 13 | 2,457 | ₹194,103 |
| S-HNI (Min) | 14 | 2,646 | ₹209,034 |
| B-HNI (Min) | 67 | 12,663 | ₹1,000,377 |
Financial Statements Amount in ₹ Crore
| Metric | 30 Sep 2025 | 31 Mar 2025 | 31 Mar 2024 |
|---|---|---|---|
| Revenue | 50 | 71 | 48 |
| EBITDA | 19 | 29 | 19 |
| Profit After Tax | 13 | 19 | 10 |
| Net Worth | 59 | 46 | 27 |
| Total Assets | 107 | 89 | 51 |
| Reserves & Surplus | 28 | 16 | 26 |
| Total Borrowing | 23 | 19 | 16 |
Valuation & Key Ratios
Grey Market Premium (GMP)
GMP is an unofficial grey market indicator and does not guarantee actual listing price. Invest at your own risk.
Objects of the Issue
- Funding capital expenditure towards establishment of New IVF Centers of the Company. – 50.00
- Repayment/pre-payment, in full or in part, of certain outstanding loans availed by the Company. – 20.00
- General Corporate Purpose –
Company Overview
Incorporated in March 2015, Gaudium IVF and Women Health Limited have engaged in In Vitro Fertilization (IVF) treatments throughout India and have expanded into several states utilizing a hub-and-spoke model.
The company operates over thirty locations, which include seven hubs (centres) and twenty-eight spokes. The organization has entered into a strategic alliance with Infertility Experts, known as Spokes, to achieve the mutual objective of raising awareness regarding Assisted Reproductive Technology (ART) and In Vitro Fertilization (IVF) treatments.
The company serves patients from various countries, including Canada, the United Kingdom, the United States, Kenya, South Africa, and Oman.
The company has centres in major cities: two in Delhi (Janakpuri, Kailash Colony), and one each in Mumbai (Khar West), Ludhiana, Srinagar, Patna, and Bangalore, covering key locations across India.
The company offers specialized fertility services, including In Vitro Fertilization (IVF), Intracytoplasmic Sperm Injection (ICSI), Intrauterine Insemination (IUI), and ovulation induction. Our treatments are designed for various infertility challenges for both genders. We also provide comprehensive gynaecological care for PCOD/PCOS and endometriosis, as well as high-risk pregnancy management for women with complex fertility histories or health conditions.
The facilities provide a comprehensive range of male infertility treatments, including advanced sperm retrieval techniques.
Competitive Strength
- Patient-Centric Approach
- Expert team
- Using next-gen INTEGRA Ti labs for ICSI.
- Highly Technical USG Guided Services
- Established central hubs in prime urban locations, including Mumbai, Bangalore, Delhi NCR, and Patna.
- Asset Light Business Model